MCM
IBRX icon

Manchester Capital Management’s ImmunityBio IBRX Stock Holding History

Manchester Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-264
Closed -$1K – 1050
2022
Q1 		$1K Hold
264
– – ﹤0.01% 939
2021
Q4 		$2K Sell
264
-44
-14% -$331 ﹤0.01% 846
2021
Q3 		$3K Hold
308
– – ﹤0.01% 793
2021
Q2 		$4K Hold
308
– – ﹤0.01% 593
2021
Q1 		$7K Buy
+308
New +$7.99K ﹤0.01% 509

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Manchester Capital Management's IBRX Position: Q2 2022 in Review

Manchester Capital Management sold out of ImmunityBio (IBRX) in Q2 2022, closing a stake of 264 shares — an estimated $1K sold.

Manchester Capital Management first reported a position in IBRX in Q1 2021 and held it in 5 quarters. The position peaked at $7K in Q1 2021. 131 funds tracked by Wall St. Rank hold IBRX as of Q2 2022.

  • Manchester Capital Management reported no remaining ImmunityBio position as of Q2 2022 after selling out during the quarter.
  • Manchester Capital Management sold 264 ImmunityBio shares in Q2 2022, an estimated $1K.
  • Manchester Capital Management first reported a position in ImmunityBio in Q1 2021 and held it in 5 quarters.
  • Manchester Capital Management's ImmunityBio position peaked at $7K in Q1 2021.
  • 131 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2022.

Based on Manchester Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.